An Intestinal Epithelium-Specific Cytochrome P450 Reductase-Knockout Mouse Model: Direct Evidence for A Role of Intestinal Cytochromes P450 in First-pass Clearance of Oral Nifedipine

Qing-Yu Zhang,Cheng Fang,D. Dunbar,L. Kaminsky,Xinxin,Ding

Abstract:To determine the in vivo function of intestinal cytochrome P450 (P450) enzymes, we have generated an intestinal epithelium (IE)-specific P450 reductase gene (Cpr) knockout mouse model (designated IE-Cpr-null). In the IE-Cpr-null mouse, CPR expression was abolished in IE cells; however, CPR expression was not altered in other tissues examined. The loss of CPR expression in the small intestine (SI) led to increased expression of several P450 proteins examined, including CYP1A1, CYP2B, CYP2C, and CYP3A. Interestingly, the expression of CYP1A1 was also increased in the liver, kidney, and lung of the IE-Cpr-null mice, compared to WT littermates, a result strongly supporting the notion that SI metabolism of putative dietary CYP1A1 inducers can influence the systemic bioavailability of these inducers. The rates of SI microsomal metabolism of nifedipine (NFP) in the IE-Cpr-null mice were ~10% of the rates in WT littermates, despite the compensatory expression of multiple P450 enzymes in the SI. Furthermore, the area-under-the-concentration-time-curve (AUC) values for blood NFP (dosed at 10 mg/kg) levels were 1.6-fold higher in IE-Cpr-null mice than in WT littermates, when NFP was given orally; in contrast, the AUC values were comparable for the two strains when NFP was given intravenously. This result directly demonstrated that P450-catalyzed NFP metabolism in the SI plays an important role in the first-pass clearance of oral NFP. Our findings indicate that the IE-Cpr-null mouse model can be used to study the in vivo function of intestinal P450 enzymes in the clearance of oral drugs and other xenobiotics. of the viability, fertility, growth rates, and potential embryonic lethality. We have also monitored the occurrence of compensatory expression changes for selected P450 enzymes in the SI and in several extra-gut organs. Finally, we have used the IE-Cpr-null mouse model to study the role of SI in the first-pass metabolism of NFP, a CYP3A substrate. Our results demonstrate that the IE-Cpr-null mouse model can be used to study the in vivo function of intestinal P450 enzymes in the clearance of oral drugs and other xenobiotics.